Your session is about to expire
← Back to Search
ANAVEX2-73 for Alzheimer's Disease (ATTENTION-AD Trial)
ATTENTION-AD Trial Summary
This trial is testing a new drug to see if it is safe and effective when taken every day.
ATTENTION-AD Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ATTENTION-AD Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not abused drugs or alcohol in the last two years and will pass a drug test.I live at home or in an assisted-living facility.I have someone who spends at least 10 hours a week with me to help with my study needs.
- Group 1: Active
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are the test subjects in this trial restricted to those over the age of 20?
"This study is investigating whether the experimental treatment is effective for patients that are aged 55 to 85."
Are there multiple sites running this clinical trial in this city?
"The Toronto Memory Program, Bay Crest Health Sciences, Kawartha Centre, and 5 other locations are currently running this clinical trial."
What other medical research has there been on ANAVEX2-73?
"ANAVEX2-73 was first researched in 2019 by MAC Clinical Research. Since then, there have been 4 completed trials and presently there are 2 studies actively recruiting patients. The majority of these studies are located in Toronto, Alberta."
This study is helping how many people?
"That is correct. The online clinicaltrials.gov registry reflects that this study is still recruiting patients. This study was first advertised on October 10th, 2019 and was updated as recently as July 12th, 2022. There are currently 5 sites where this trial is taking place and a total of 450 patients are desired."
What groundbreaking discoveries can be expected from this research?
"ANAVEX2-73 has been under clinical investigation since 2019. The first trial, sponsored by Anavex Germany GmbH, took place that year and included 450 participants. After the initial study in 2019, ANAVEX2-73 received Phase 2 & 3 drug approval. As of now, there are 2 live studies for ANAVEX2-73 being conducted in 32 cities across 5 countries."
Could I be a subject in this experiment?
"Alzheimer's disease patients that are aged between 55 and 85 can apply to be a part of this clinical trial. The goal is to have around 450 participants."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger